3378 — Hanx Biopharmaceuticals (Wuhan) Co Income Statement
0.000.00%
Last trade - 00:00- HK$4.38bn
- HK$4.44bn
Annual income statement for Hanx Biopharmaceuticals (Wuhan) Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PRESS |
| Standards: | IFRS | IFRS | — |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Depreciation and Amortization | |||
| Unusual Expense / Income | |||
| Other Operating Expenses | |||
| Total Operating Expenses | 94.6 | 119 | 133 |
| Operating Profit | -94.6 | -119 | -133 |
| Total Net Non Operating Interest Income / Expense | |||
| Net Income Before Taxes | -93.4 | -123 | -145 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -85.2 | -117 | -131 |
| Minority Interest | |||
| Net Income Before Extraordinary Items | |||
| Net Income | -76.1 | -116 | -131 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -76.1 | -116 | -131 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -0.558 | -0.799 | -0.896 |